MBRX just significantly strengthened its competitive moat with a new Australian patent for Annamycin (stabilized preliposomal lyophilizate), extending protection until at least 2040.This global IP expansion fuels the bull case, but watch the chart! A sustained move above its key moving average is crucial for a potential stock breakout. #Moleculin #Biotech #Patent
إخلاء المسؤولية
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
إخلاء المسؤولية
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.